1.5T hours with Assessment – Optometry Australia IoE Quality Assurance | TBC in New Zealand
Topical corticosteroids represent one of the most potent and efficacious treatments for anterior segment ocular inflammation.1,2 Possessing variable therapeutic effect, dependent upon active drug potency and penetrance, topical anti-inflammatory preparations elicit therapeutic effect by directly targeting ocular structures.2,3 Flarex (fluorometholone acetate 0.1%) suspension eye drops were withdrawn from the Australian pharmaceutical market in June 2024, with the remaining supply continuing to be available until it was exhausted. Manufacturer Novartis Pharmaceuticals Australia Pty Ltd cited changes to commercial viability as justification for the discontinuation.4 Thomas Ford considers the implications for clinical practice and the available alternatives for effective management of ophthalmic disease…Read and take test.
